Redmile Group LLC Purchases 449,540 Shares of REGENXBIO Inc. (RGNX)

Redmile Group LLC increased its position in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 35.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,718,671 shares of the biotechnology company’s stock after acquiring an additional 449,540 shares during the period. REGENXBIO comprises approximately 2.1% of Redmile Group LLC’s portfolio, making the stock its 17th biggest holding. Redmile Group LLC owned about 5.56% of REGENXBIO worth $33,944,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the stock. Perceptive Advisors LLC raised its holdings in shares of REGENXBIO by 8.9% during the first quarter. Perceptive Advisors LLC now owns 1,396,244 shares of the biotechnology company’s stock worth $26,947,000 after acquiring an additional 113,958 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of REGENXBIO by 4.3% during the second quarter. JPMorgan Chase & Co. now owns 1,226,835 shares of the biotechnology company’s stock worth $24,230,000 after acquiring an additional 51,041 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of REGENXBIO by 10.3% during the second quarter. Vanguard Group Inc. now owns 1,082,461 shares of the biotechnology company’s stock worth $21,379,000 after acquiring an additional 100,944 shares in the last quarter. Citadel Advisors LLC raised its holdings in shares of REGENXBIO by 65.4% during the second quarter. Citadel Advisors LLC now owns 926,176 shares of the biotechnology company’s stock worth $18,292,000 after acquiring an additional 366,289 shares in the last quarter. Finally, State Street Corp raised its holdings in shares of REGENXBIO by 178.1% during the second quarter. State Street Corp now owns 880,844 shares of the biotechnology company’s stock worth $17,399,000 after acquiring an additional 564,129 shares in the last quarter. Institutional investors and hedge funds own 73.26% of the company’s stock.

REGENXBIO Inc. (NASDAQ:RGNX) traded up 1.51% during trading on Friday, reaching $33.65. 289,170 shares of the company’s stock traded hands. The firm has a 50 day moving average price of $30.08 and a 200-day moving average price of $30.08. REGENXBIO Inc. has a 12 month low of $15.25 and a 12 month high of $33.95. The firm’s market cap is $1.04 billion.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.34. REGENXBIO had a negative net margin of 839.87% and a negative return on equity of 38.74%. The firm had revenue of $6.56 million for the quarter. On average, analysts forecast that REGENXBIO Inc. will post ($2.94) earnings per share for the current fiscal year.

In other REGENXBIO news, Director Donald J. Hayden, Jr. sold 20,000 shares of the business’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $24.95, for a total transaction of $499,000.00. Following the sale, the director now directly owns 20,000 shares of the company’s stock, valued at approximately $499,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Kenneth T. Mills sold 6,500 shares of the business’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $18.66, for a total transaction of $121,290.00. Following the sale, the insider now directly owns 112,000 shares in the company, valued at $2,089,920. The disclosure for this sale can be found here. Insiders have sold a total of 184,640 shares of company stock worth $4,865,890 over the last three months. Insiders own 17.00% of the company’s stock.

RGNX has been the subject of several recent research reports. BidaskClub upgraded REGENXBIO from a “hold” rating to a “buy” rating in a report on Saturday, August 12th. Zacks Investment Research upgraded REGENXBIO from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a report on Saturday, August 12th. Evercore ISI initiated coverage on REGENXBIO in a report on Wednesday, August 16th. They set an “outperform” rating and a $25.00 price objective for the company. Bank of America Corporation increased their price objective on REGENXBIO from $29.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, September 21st. Finally, Chardan Capital increased their price objective on REGENXBIO from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, August 9th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. REGENXBIO presently has an average rating of “Buy” and an average price target of $36.20.

TRADEMARK VIOLATION WARNING: “Redmile Group LLC Purchases 449,540 Shares of REGENXBIO Inc. (RGNX)” was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://transcriptdaily.com/2017/10/08/redmile-group-llc-purchases-449540-shares-of-regenxbio-inc-rgnx.html.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Institutional Ownership by Quarter for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply